Related Experiment Video
Updated: Jul 18, 2026
10:52
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
Published on: December 17, 2010
Autoimmune hypophysitis treated with intravenous glucocorticoid therapy
Ikuyo Miyake1, Yasuharu Takeuchi, Terukazu Kuramoto
1Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine.
Internal Medicine (Tokyo, Japan)
|December 2, 2006
Summary
Autoimmune hypophysitis, a pituitary inflammation, can cause headaches and vision loss. Prompt steroid treatment effectively reduced pituitary swelling and restored function in a patient with this condition.
Area of Science:
- Endocrinology
- Neuroimaging
- Immunology
Background:
- Autoimmune hypophysitis is an inflammatory condition affecting the pituitary gland.
- It can present with diverse symptoms including headaches, visual disturbances, and hormonal deficiencies.
Observation:
- A 46-year-old male presented with frontal headache, visual field defect, and fatigue.
- Brain MRI revealed pituitary gland enlargement with extension towards the optic chiasm and dural enhancement.
- Laboratory tests indicated decreased levels of ACTH, thyroxine, gonadotropins, and reduced 17-OHCS excretion, alongside elevated anti-thyroglobulin antibodies.
Findings:
- Intravenous and oral corticosteroid therapy led to clinical symptom resolution and recovery of pituitary function.
- Follow-up MRI demonstrated significant reduction in pituitary mass size.
- The patient's visual dysfunction also improved with steroid treatment.
Implications:
- Early glucocorticoid administration is an effective treatment for autoimmune hypophysitis.
- This approach can reverse pituitary dysfunction and improve visual deficits.
- Prompt diagnosis and intervention are crucial for managing autoimmune hypophysitis.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...